Nektar Therapeutics
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NKTR research report →
Companywww.nektar.com
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates.
- CEO
- Howard W. Robin
- IPO
- 1994
- Employees
- 61
- HQ
- San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $1.34B
- P/E
- -10.76
- P/S
- 24.15
- P/B
- 2.95
- EV/EBITDA
- -11.28
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.38%
- Op Margin
- -224.88%
- Net Margin
- -284.18%
- ROE
- -87.00%
- ROIC
- -17.17%
Growth & Income
- Revenue
- $55.23M · -43.89%
- Net Income
- $-164,076,000 · -37.92%
- EPS
- $-9.73 · -12.10%
- Op Income
- $-130,770,999
- FCF YoY
- -17.78%
Performance & Tape
- 52W High
- $109.00
- 52W Low
- $7.99
- 50D MA
- $78.72
- 200D MA
- $57.00
- Beta
- 1.25
- Avg Volume
- 1.03M
Get TickerSpark's AI analysis on NKTR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 18, 26 | Zalevsky Jonathan | sell | 180 |
| Feb 18, 26 | ROBIN HOWARD W | sell | 423 |
| Jan 20, 26 | Zalevsky Jonathan | sell | 3,867 |
| Dec 22, 25 | Zalevsky Jonathan | other | 6,250 |
| Dec 22, 25 | Zalevsky Jonathan | other | 25,000 |
| Dec 22, 25 | ROBIN HOWARD W | other | 86,667 |
| Dec 22, 25 | ROBIN HOWARD W | other | 21,667 |
| Nov 21, 25 | Zalevsky Jonathan | other | 2,666 |
| Nov 25, 25 | Zalevsky Jonathan | sell | 1,157 |
| Nov 21, 25 | Zalevsky Jonathan | other | 4,766 |
Our NKTR Coverage
We haven't published any research on NKTR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NKTR Report →